A practical reference on melanotan II: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-03 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
=== Withdrawal === Abrupt or rapid discontinuation of mianserin may provoke a withdrawal, the effects of which may include depression, anxiety, panic attacks, decreased appetite or anorexia, insomnia, diarrhea, nausea and vomiting, and flu-like symptoms, such as allergies or pruritus, among others.
After the Qatari Ministry of Defence announced on 2 March that two Iranian drones attacked Qatari gas facilities, followed closely by an announcement from QatarEnergy that all gas production in the country had been halted, European natural gas prices nearly doubled. This raised concerns over energy security and fertiliser costs. EU natural gas prices decreased again to a less-high €48/MWh on Wednesday 4 March. The Iran conflict also bolstered the necessity for renewable energy, as solar and wind power can reduce vulnerability to external supply and decentralised power generation that offers greater autonomy from global energy markets. With fluctuating oil prices, renewable energy has become significantly more cost-competitive. April 2026 was the strongest month of electric vehicle sales on record in Europe. Shell plc's CEO warned that Europe could face shortages of fuel by April. British supermarket chain Asda warned that it was already facing shortages of fuel at their fuel stations. In addition to broader fuel supply disruptions, reports in April 2026 indicated significant impacts on global energy and aviation markets linked to tensions in the Strait of Hormuz during the Iran–United States conflict. Restricted maritime traffic was reported to have contributed to supply constraints in oil and jet fuel, affecting global energy flows and increasing market volatility. The disruption contributed to sharp increases in global energy prices.
[We] have to act according not only to the facts but to the ... evidence. I am sure you understand that these are very grave accusations." The European Ombudsman, Emily O'Reilly, was, however critical of the response of Von der Leyen and fellow politicians and institutions, highlighting the lack of progress shown by von der Leyen following her pledge that transparency would be a core part of her mandate when she became European Commission President. O'Reilly called for a body to be created with real investigatory and sanctions powers. The Belgian Prime Minister, Alexander De Croo, was also critical of the European institutions in his response, stating that "Belgian justice is doing what, at first sight, the European Parliament hasn't done." "The European Parliament has a lot of means to regulate itself. It turns out that this is largely a system of auto-control based on voluntary efforts, which has clearly not been sufficient." Annalena Baerbock, the German Minister for Foreign Affairs, highlighted that the scandal is leading to concerns from citizens and affects the credibility and legitimacy of the institutions of the European Union. On 15 December the European People's Party (EPP) reacted by declaring, "We need to discuss hypocrisy ... This is an S&D scandal." In an attempt to focus the scandal on the Progressive Alliance of Socialists and Democrats Group (S&D), rather than the European Parliament as a whole, they continued, "There has been a consistent effort to turn #Qatargate into an institutional issue alone. But this scandal is not an orphan. ... It has an address.
Sources: en.wikipedia.org
In 1884, Svante Arrhenius attributed the properties of acidity to hydrogen cations (H+), later described as protons or hydrons. An Arrhenius acid is a substance that, when added to water, increases the concentration of H+ ions in the water. Chemists often write H+(aq) and refer to the hydrogen cation when describing acid–base reactions but the free hydrogen nucleus, a proton, does not exist alone in water, it exists as the hydronium ion (H3O+) or other forms (H5O2+, H9O4+). Thus, an Arrhenius acid can also be described as a substance that increases the concentration of hydronium ions when added to water. Examples include molecular substances such as hydrogen chloride and acetic acid. An Arrhenius base, on the other hand, is a substance that increases the concentration of hydroxide (OH−) ions when dissolved in water. This decreases the concentration of hydronium because the ions react to form H2O molecules:
The war's ground phase was officially designated Operation Desert Saber. The first units to move into Iraq were three patrols of the British Special Air Service's B squadron, call signs Bravo One Zero, Bravo Two Zero, and Bravo Three Zero, in late January. These eight-man patrols landed behind Iraqi lines to gather intelligence on the movements of Scud mobile missile launchers, which could not be detected from the air, as they were hidden under bridges and camouflage netting during the day. Other objectives included the destruction of the launchers and their fiber-optic communications arrays that lay in pipelines and relayed coordinates to the TEL operators launching attacks against Israel. The operations were designed to prevent any possible Israeli intervention. Due to lack of sufficient ground cover to carry out their assignment, One Zero and Three Zero abandoned their operations, while Two Zero remained, and was later compromised, with only Sergeant Chris Ryan escaping to Syria. Elements of the 2nd Brigade, 1st Battalion 5th Cavalry of the 1st Cavalry Division of the US Army performed a direct attack into Iraq on 15 February 1991, followed by one in force on 20 February that led directly through seven Iraqi divisions which were caught off guard. On 17 January 1991 the 101st Airborne Division Aviation Regiment fired the first shots of the war when eight AH-64 helicopters successfully destroyed two Iraqi early warning radar sites.
=== Biosynthesis === Similar to other pheromone biosynthesis reactions, female cabbage looper pheromone production initiates with synthesis of 16 and 18-carbon fatty acids. This is followed by desaturation at C1 and chain shortening by two or four carbons. Finally, the fatty acid is reduced and acetylated to form an acetate ester. The result is a blend of different female pheromone compounds at a consistent ratio. This ratio can be highly altered by mutations in chain shortening proteins, demonstrating that the chain shortening step is important for determining the ratio of pheromones in the final blend. As a species, the cabbage looper does not hormonally regulate pheromone production. Stage specific proteins correspond to the development of the pheromone gland. The immature gland lacks numerous enzymes crucial to pheromone biosynthesis, such as fatty acid synthetase and acetyltransferase, which is why the looper cannot produce pheromones prior to the adult stage. Upon complete development of the pheromone glands at the adult stage, pheromones are constantly produced.
Sources: en.wikipedia.org
== Planar chromatography == The retardation factor, RF, is commonly used in paper chromatography and thin layer chromatography (TLC) for analyzing and comparing different substances. It can be mathematically described by the following ratio:
==== GBA gene ==== The GBA gene is associated with lysosome storage and autophagy. GBA encodes the enzyme glucocerebrosidase (GCase), necessary for breaking down glucosylceramide (GlcCer). Mutations in GBA can cause modifications in GCase protein structure, decreases in GCase activity and protein levels, and the accumulation of GlcCer in the cell. Approximately 5–15% of PD patients have mutations in the GBA gene. Mendelian genetics are not strictly observed in GBA mutations in PD. Both gain-of-function and loss-of-function GBA mutations are associated with increased risk of PD. GBA is one of a number of pleiotropic genes which have multiple effects in the body, that have been linked to PD risk. Mutations in GBA1 can cause either complete loss‐of‐function and the lysosomal disorder Gaucher's disease, or partial loss‐of‐function with an increased risk for PD. Mutations in EPG5 are implicated in a range of dysfunctions, from severe (Vici syndrome), to moderate (atypical parkinsonism) and mild (typical PD). Microdeletions at 22q11.2 have been variously linked to PD, schizophrenia, and DiGeorge syndrome.
=== Multicellularity === Multicellular behavior is demonstrated by microorganisms that are cloned from a single cell and form visible microbial colonies. A microbial consortium of two or more species can form a biofilm by the secretion of extracellular polymeric substances (EPSs). Slime molds consist of different groups of microorganisms grouped together in a multicellular-like fashion. The first evidence of multicellularity in an organism comes from cyanobacteria-like organisms that lived between 3 and 3.5 billion years ago. Cyanobacteria are variable in morphology, filamentous forms exhibit functional cell differentiation such as heterocysts (for nitrogen fixation), akinetes (resting stage cells), and hormogonia (reproductive, motile filaments). These, together with the intercellular connections they possess, are considered the first signs of multicellularity.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.